Hack, Stephen P
Genentech
3 papers on CoChatORCID 0000-0002-0640-5709
Most cited papers
- Verified
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 562
- Verified
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 545
- Verified
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology
Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer
Cited by 286
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free